Influenza: A Global Perspective

Pediatric Clinics of North America

Volumn 64, Issue 4, 2017, Pages 911-936

  Rotrosen, Elizabeth T ^a   Neuzil, Kathleen M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral medications; Children; Influenza; Influenza vaccines; Vaccine policy

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; ANTIVIRUS AGENT;

ANTIBODY RESPONSE; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; DRUG EFFICACY; DRUG SAFETY; GOVERNMENT REGULATION; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; OUTCOME ASSESSMENT; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; VACCINE IMMUNOGENICITY; CHILD; GLOBAL HEALTH; INFLUENZA, HUMAN; PREVENTIVE HEALTH SERVICE; PROCEDURES;

ANTIVIRAL AGENTS; CHILD; GLOBAL HEALTH; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 85025435096     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2017.03.007     Document Type: Review

References (85)

1. World Health Organization. Influenza (Seasonal) fact sheet. 2014. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed September 10, 2016.
2. Grijalva, C.G., Zhu, Y., Williams, D.J., et al. Association between hospitalization with community-acquired laboratory-confirmed influenza pneumonia and prior receipt of influenza vaccination. JAMA 314:14 (2015), 1488–1497.
3. Manzoli, L., Schioppa, F., Boccia, A., et al. The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J 26:2 (2007), 97–106.
4. Poehling, K.A., Edwards, K.M., Weinberg, G.A., et al. The underrecognized burden of influenza in young children. N Engl J Med 355:1 (2006), 31–40.
5. Silvennoinen, H., Peltola, V., Lehtinen, P., et al. Clinical presentation of influenza in unselected children treated as outpatients. Pediatr Infect Dis J 28:5 (2009), 372–375.
6. Peltola, V., Ziegler, T., Ruuskanen, O., Influenza A and B virus infections in children. Clin Infect Dis 36:3 (2003), 299–305.
7. Neuzil, K.M., Zhu, Y., Griffin, M.R., et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 185:2 (2002), 147–152.
8. Centre for Disease Control and Prevention. Flu symptoms and complications. 2016 Available at: http://www.cdc.gov/flu/about/disease/complications.htm. Accessed December 7, 2016.
9. Glezen, W.P., Couch, R.B., Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 298:11 (1978), 587–592.
10. Neuzil, K.M., Mellen, B.G., Wright, P.F., et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 342:4 (2000), 225–231.
11. Poehling, K.A., Edwards, K.M., Griffin, M.R., et al. The burden of influenza in young children, 2004-2009. Pediatrics 131:2 (2013), 207–216.
12. Grijalva, C.G., Craig, A.S., Dupont, W.D., et al. Estimating influenza hospitalizations among children. Emerg Infect Dis 12:1 (2006), 103–109.
13. Dawood, F.S., Fiore, A., Kamimoto, L., et al. Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. J Pediatr 157:5 (2010), 808–814.
14. Chaves, S.S., Perez, A., Farley, M.M., et al. The burden of influenza hospitalizations in infants from 2003 to 2012, United States. Pediatr Infect Dis J 33:9 (2014), 912–919.
15. Gessner, B.D., Brooks, W.A., Neuzil, K.M., et al. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). Vaccine 31:32 (2013), 3222–3228.
16. Heikkinen, T., Silvennoinen, H., Peltola, V., et al. Burden of influenza in children in the community. J Infect Dis 190:8 (2004), 1369–1373.
17. Dawood, F.S., Chaves, S.S., Pérez, A., et al. Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010. J Infect Dis 209:5 (2014), 686–694.
18. Dawood, F.S., Fiore, A., Kamimoto, L., et al. Influenza-associated pneumonia in children hospitalized with laboratory-confirmed influenza, 2003-2008. Pediatr Infect Dis J 29:7 (2010), 585–590.
19. Finelli, L., Fiore, A., Dhara, R., et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 122:4 (2008), 805–811.
20. Centre for Disease Control and Prevention. Influenza-associated pediatric mortality. FluView. 2016. Available at: https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. Accessed December 16, 2016.
21. Bhat, N., Wright, J.G., Broder, K.R., et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 353:24 (2005), 2559–2567.
22. Wong, K.K., Jain, S., Blanton, L., et al. Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics 132:5 (2013), 796–804.
23. Brooks, W.A., Zaman, K., Lewis, K.D., et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health 4:12 (2016), e946–e954.
24. Victor, J.C., Lewis, K.D., Diallo, A., et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health 4:12 (2016), e955–e965.
25. Belshe, R.B., Gruber, W.C., Mendelman, P.M., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:2 (2000), 168–175.
26. Belshe, R.B., Mendelman, P.M., Treanor, J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 338:20 (1998), 1405–1412.
27. Hoberman, A., Greenberg, D.P., Paradise, J.L., et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 290:12 (2003), 1608–1616.
28. Clover, R.D., Crawford, S., Glezen, W.P., et al. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 163:2 (1991), 300–304.
29. Nair, H., Brooks, W.A., Katz, M., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 378:9807 (2011), 1917–1930.
30. Azziz-Baumgartner, E., Alamgir, A.S., Rahman, M., et al. Incidence of influenza-like illness and severe acute respiratory infection during three influenza seasons in Bangladesh, 2008-2010. Bull World Health Organ 90:1 (2012), 12–19.
31. Fox, J.P., Cooney, M.K., Hall, C.E., et al. Influenza virus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 116:2 (1982), 228–242.
32. Longini, I.M. Jr., Koopman, J.S., Monto, A.S., et al. Estimating household and community transmission parameters for influenza. Am J Epidemiol 115:5 (1982), 736–751.
33. Wright, P., Influenza in the family. N Engl J Med 343:18 (2000), 1331–1332.
34. Hall, C.B., Douglas, R.G. Jr., Nosocomial influenza infection as a cause of intercurrent fevers in infants. Pediatrics 55:5 (1975), 673–677.
35. Klimov, A.I., Rocha, E., Hayden, F.G., et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 172:5 (1995), 1352–1355.
36. Frank, A.L., Taber, L.H., Wells, C.R., et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 144:5 (1981), 433–441.
37. Memoli, M.J., Athota, R., Reed, S., et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 58:2 (2014), 214–224.
38. Neuzil, K.M., Hohlbein, C., Zhu, Y., Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 156:10 (2002), 986–991.
39. World Health Organization. Global Influenza Surveillance and Response System (GISRS). 2017. Available at: http://www.who.int/influenza/gisrs_laboratory/en/. Accessed January 3, 2017.
40. Brooks, W.A., Goswami, D., Rahman, M., et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J 29:3 (2010), 216–221.
41. Tisa, V., Barberis, I., Faccio, V., et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg 57:1 (2016), E28–E33.
42. Gemmill I. Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine 2015-2016, in Canada Communicable Disease Report. 2015. p. 227–32. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-10/ar-02-eng.php. Accessed April 18, 2017.
43. Gemmill I, Zhao L, Cochrane L. Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2016-2017, in Canada Communicable Disease Report. 2016. p. 187–91. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/16vol42/dr-rm42-9/ar-06-eng.php. Accessed April 17, 2017.
44. Fiore, A.E., Uyeki, T.M., Broder, K., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59:RR-8 (2010), 1–62.
45. Grohskopf, L.A., Sokolow, L.Z., Broder, K.R., et al. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 64:30 (2015), 818–825.
46. Neuzil KM, Ortiz JR. Influenza vaccines and vaccination strategies. In: Bloom BR, Lambert PH, editors. The vaccine book. Cambridge (MA): USA Academic Press. p. 423–44.
47. Keitel, W.A., Neuzil, K.M., Traenor, J., Immunogenicity and efficacy of inactivated/live virus seasonal and pandemic vaccines. Webster, R.G., et al. (eds.) Textbook of influenza, 2013, Wiley Blackwell, West Sussex (United Kingdom).
48. France, E.K., Glanz, J.M., Xu, S., et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med 158:11 (2004), 1031–1036.
49. Hambidge, S.J., Glanz, J.M., France, E.K., et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 296:16 (2006), 1990–1997.
50. Glanz, J.M., Newcomer, S.R., Hambidge, S.J., et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med 165:8 (2011), 749–755.
51. Vesikari, T., Knuf, M., Wutzler, P., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365:15 (2011), 1406–1416.
52. Global advisory committee on vaccine safety, 11-12 December 2013. Wkly Epidemiol Rec 89:7 (2014), 53–60.
53. Tse, A., Tseng, H.F., Greene, S.K., et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 30:11 (2012), 2024–2031.
54. Committee on Infectious Diseases, Recommendations for prevention and control of influenza in children, 2016-2017. Pediatrics, 138(4), 2016.
55. Centers for Disease Control and Prevention, Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)–United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 61:32 (2012), 613–618.
56. Englund, J.A., Walter, E.B., Fairchok, M.P., et al. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 115:4 (2005), 1039–1047.
57. Grohskopf, L.A., Sokolow, L.Z., Broder, K.R., et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 65:5 (2016), 1–54.
58. Osterholm, M.T., Kelley, N.S., Sommer, A., et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:1 (2012), 36–44.
59. Neuzil, K.M., Dupont, W.D., Wright, P.F., et al. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20:8 (2001), 733–740.
60. Jain, V.K., Rivera, L., Zaman, K., et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 369:26 (2013), 2481–2491.
61. Ferdinands, J.M., Olsho, L.E., Agan, A.A., et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis 210:5 (2014), 674–683.
62. Flannery, B., Reynolds, S.B., Blanton, L., et al. Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010-2014. Pediatrics, 139(5), 2017.
63. Nolan, T., Bravo, L., Ceballos, A., et al. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children. Vaccine 32:46 (2014), 6146–6156.
64. Johnson, P.R., Feldman, S., Thompson, J.M., et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 154:1 (1986), 121–127.
65. Hoft, D.F., Babusis, E., Worku, S., et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 204:6 (2011), 845–853.
66. Wright, P.F., Hoen, A.G., Ilyushina, N.A., et al. Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine. Open Forum Infect Dis, 3(2), 2016, ofw108.
67. Belshe, R.B., Gruber, W.C., Mendelman, P.M., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 181:3 (2000), 1133–1137.
68. Forrest, B.D., Pride, M.W., Dunning, A.J., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 15:7 (2008), 1042–1053.
69. Fleming, D.M., Crovari, P., Wahn, U., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 25:10 (2006), 860–869.
70. Belshe, R.B., Edwards, K.M., Vesikari, T., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356:7 (2007), 685–696.
71. Ashkenazi, S., Vertruyen, A., Arístegui, J., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 25:10 (2006), 870–879.
72. Flannery, B., Clippard, J., Zimmerman, R.K., et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep 64:1 (2015), 10–15.
73. Skowronski, D.M., Janjua, N.Z., De Serres, G., et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 55:3 (2012), 332–342.
74. Flannery, B., LAIV vs IIV effectiveness: summary of evidence since 2009. 2016, Centers for Disease Control and Prevention (CDC) Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/influenza-07-flannery.pdf Accessed April 17, 2017.
75. National Advisor Committee on Immunization (NACI). Addendum - LAIV Use in children and adolescents. Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2016-2017. 2016. Available at: http://www.phac-aspc.gc.ca/naci-ccni/flu-2016-grippe-addendum-children-enfants-eng.php. Accessed April 17, 2017.
76. WHO, Vaccines against influenza. WHO position paper. Wkly Epidemiol Rec 87:47 (2012), 461–476.
77. Zaman, K., Roy, E., Arifeen, S.E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359:15 (2008), 1555–1564.
78. Madhi, S.A., Cutland, C.L., Kuwanda, L., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 371:10 (2014), 918–931.
79. Tapia, M.D., Sow, S.O., Tamboura, B., et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 16:9 (2016), 1026–1035.
80. CDC. Influenza antiviral medications: summary for clinicians. 2016. Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed January 17, 2017.
81. CDC. Antiviral drug resistance among influenza viruses. 2016. Available at: https://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm. Accessed January 17, 2017.
82. Vesikari, T., Fleming, D.M., Aristegui, J.F., et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 118:6 (2006), 2298–2312.
83. Tam, J.S., Capeding, M.R., Lum, L.C., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26:7 (2007), 619–628.
84. Bracco Neto, H., Farhat, C.K., Tregnaghi, M.W., et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 28:5 (2009), 365–371.
85. Madhi, S.A., Dittmer, S., Kuwanda, L., et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS 27:3 (2013), 369–379.